Bcg vaccine - Biologic Drug Details

Summary for bcg vaccine

Tradenames:	2
High Confidence Patents:	0
Applicants:	2
BLAs:	2
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for bcg vaccine

Recent Clinical Trials for bcg vaccine

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Stanford University	PHASE4
Infectious Diseases Research Collaboration, Uganda	PHASE4
University of California, San Francisco	PHASE4

See all bcg vaccine clinical trials

Pharmacology for bcg vaccine

Physiological Effect	Actively Acquired Immunity Increased Immunologically Active Molecule Activity Increased Macrophage Proliferation
Established Pharmacologic Class	Live Attenuated Bacillus Calmette-Guerin Immunotherapy Live Attenuated Bacillus Calmette-Guerin Vaccine
Chemical Structure	BCG Vaccine Vaccines, Attenuated

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for bcg vaccine Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for bcg vaccine Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for bcg vaccine Derived from Patent Text Search

No patents found based on company disclosures

Bcg vaccine Market Analysis and Financial Projection

Last updated: February 13, 2026

What Are the Market Dynamics for the BCG Vaccine?

The Bacillus Calmette-Guérin (BCG) vaccine remains the only licensed vaccine for tuberculosis (TB) prevention for over 90 years. Market growth hinges on TB incidence rates, manufacturing capacity, global vaccination policies, and emerging markets.

Key Drivers

• TB Burden: WHO reports approximately 10 million TB cases globally in 2021, with high prevalence in Asia and Africa. Regions with high TB burden, especially India and China, are primary markets. The demand is driven by TB prevalence, public health policies, and vaccination coverage.

• Vaccination Policies: Countries' vaccination strategies influence demand. Many nations administer BCG universally at birth, especially in high-incidence regions. Some low-incidence countries only vaccinate high-risk groups, limiting market size.

• Manufacturing Capacity & Supply Constraints: BCG vaccine production is limited, with only a handful of global manufacturers (e.g., Serum Institute of India, Sanofi Pasteur). Capacity expansions are infrequent, impacting supply and price stability.

• Emergence of New TB Vaccines: Novel candidates in Phase II and III trials threaten to disrupt the BCG-dominant market. Substitution depends on efficacy, safety, and regulatory approval speed.

• Private and Public Funding: Investments from governments and global health organizations, especially for TB control programs, align with TB incidence trends, influencing market stability.

Market Challenges

• Vaccine Limitations: BCG offers inconsistent protection against adult pulmonary TB and does not prevent latent TB infection, prompting demand for more effective vaccines.

• Vaccine Manufacturing Complexity: Living bacterial vaccines require cold chain logistics and complex manufacturing, raising costs and limiting supply expansion.

• Global Health Policies: Variability in national policies causes inconsistent demand and supply chain uncertainties.

Market Segments

Segment	Characteristics
Pediatric vaccination	High coverage in TB endemic countries; largest segment for BCG.
Latent TB infection	Limited use; potential growth area for next-generation vaccines.
Adult vaccination	Minimal; BCG’s role primarily in childhood immunization.

Market Size and Projections

In 2022, the global BCG vaccine market was valued at approximately $700 million. The compound annual growth rate (CAGR) from 2023 to 2028 is projected around 2%, mainly driven by TB control programs in high-incidence countries.

What Is the Financial Trajectory for BCG Vaccine Manufacturers?

Revenue Trends

• Leading Players: Sanofi Pasteur and Serum Institute dominate production. Sanofi's BCG products generate an estimated $300 million annually, while the Serum Institute's share is around $200 million globally.

• Pricing Dynamics: Prices vary by region. High-income countries pay $10–20 per dose; low-income countries pay under $1 due to subsidies. Price stability is affected by supply constraints and manufacturing costs.

R&D Investments & Pipeline

• Next-generation vaccines: Companies like Statens Serum Institut (with their VPM1002 candidate) and Tuberculosis Vaccine Initiative are developing improved vaccines aimed at replacing or supplementing BCG.

• Regulatory progress: VPM1002 completed Phase III trials, with potential approval in the next 1–2 years, promising improved efficacy and safety.

Economic Pressures

• Cost of production: The complex manufacturing process elevates costs, limiting margins especially in low-income markets.

• Supply disruptions: Manufacturing bottlenecks, political instability, or raw material shortages can lead to market volatility.

• Pricing negotiations: International agencies leverage bulk purchasing and subsidies, keeping prices competitive but pressuring profit margins.

Future Revenue Potential

• The market could stabilize or grow modestly, contingent on new vaccine approvals and expanded vaccination policies. Overall, revenues for existing BCG vaccine producers are expected to remain between $600 million and $800 million annually over the next five years.

How Do Policy and Innovation Impact Market and Financial Outlook?

New vaccine candidates showing superior efficacy could replace BCG in some markets, depress existing revenues, or create opportunity if they are adopted as New-Standard-of-care vaccines.

Large-scale adoption of next-generation TB vaccines, if successful, could:

• Grow total TB vaccine market size to over $2 billion within a decade.
• Shift revenue streams from mature BCG products to innovative formulations.
• Prompt competitors to invest in R&D and infrastructure upgrades.

What Are the Key Takeaways?

• The BCG vaccine market remains stable, driven by high TB burden regions and existing vaccination policies.
• Supply limitations and regional policy variability pose ongoing challenges.
• The market is poised for modest growth, influenced heavily by the progress of next-generation TB vaccines.
• Revenues are concentrated among a few manufacturers; prices are region-dependent.
• Innovation and regulatory approval timelines are critical for future market dynamics and financial prospects.

FAQs

1. What factors influence BCG vaccine demand in different regions?
   TB incidence rates, vaccination policy adoption, public health funding, and local manufacturing capacity.

2. How might new TB vaccines affect existing market players?
   If approved and adopted widely, they could displace BCG, reducing demand and revenues for current manufacturers.

3. What are the main challenges for BCG vaccine supply?
   Manufacturing complexity, limited capacity, and logistical issues related to cold chain requirements.

4. Are there opportunities for new entrants in the BCG or TB vaccine market?
   Yes; especially in developing next-generation vaccines offering improved efficacy or easier logistics.

5. What geopolitical factors impact the BCG vaccine market?
   Political stability, healthcare infrastructure, and international funding programs influence procurement and distribution.

References

[1] World Health Organization (WHO). Global Tuberculosis Report 2022.
[2] MarketWatch. "Global BCG Vaccines Market Size, Share & Industry Analysis, 2022-2028."
[3] Sanofi Pasteur Corporate. Annual Reports 2022.
[4] Serum Institute of India. Business Overview 2022.
[5] Tuberculosis Vaccine Initiative (TBVI). Innovation Pipeline 2023.